Pan D, Benkato K, Han X, Zheng J, Kumar V, Wan M
Elife. 2024; 12.
PMID: 38896465
PMC: 11186630.
DOI: 10.7554/eLife.92889.
Pan D, Benkato K, Han X, Zheng J, Kumar V, Wan M
bioRxiv. 2023; .
PMID: 37961590
PMC: 10634856.
DOI: 10.1101/2023.10.26.564218.
Lee S, Seo Y, Choi J, Che X, Kim H, Eum S
Sci Rep. 2022; 12(1):21667.
PMID: 36522387
PMC: 9755294.
DOI: 10.1038/s41598-022-25174-6.
Zhang J, Cohen A, Shen B, Du L, Tasdogan A, Zhao Z
Proc Natl Acad Sci U S A. 2021; 118(25).
PMID: 34140410
PMC: 8237660.
DOI: 10.1073/pnas.2026176118.
Al-Khan A, Al Balushi N, Richardson S, Danks J
Front Vet Sci. 2021; 8:637614.
PMID: 33796580
PMC: 8008073.
DOI: 10.3389/fvets.2021.637614.
Teriparatide may accelerate the growth of a pre-existing malignant tumor in an elderly patient with osteoporosis: A case report.
Ogawa T, Ohshika S, Yanagisawa M, Kurose A, Ishibashi Y
Mol Clin Oncol. 2020; 12(2):144-147.
PMID: 31929885
PMC: 6951240.
DOI: 10.3892/mco.2019.1966.
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial.
Tabatabaei-Malazy O, Norani M, Heshmat R, Qorbani M, Vosoogh A, Afrashteh B
Iran J Public Health. 2018; 47(9):1336-1344.
PMID: 30320008
PMC: 6174042.
Effects of bone remodeling agents following teriparatide treatment.
Burkard D, Beckett T, Kourtjian E, Messingschlager C, Sipahi R, Padley M
Osteoporos Int. 2018; 29(6):1351-1357.
PMID: 29541794
DOI: 10.1007/s00198-018-4434-8.
Osteoprotection Through the Deletion of the Transcription Factor Rorβ in Mice.
Farr J, Weivoda M, Nicks K, Fraser D, Negley B, Onken J
J Bone Miner Res. 2017; 33(4):720-731.
PMID: 29206307
PMC: 5925424.
DOI: 10.1002/jbmr.3351.
MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
Canalis E
Eur J Endocrinol. 2017; 178(2):R33-R44.
PMID: 29113980
PMC: 5819362.
DOI: 10.1530/EJE-17-0920.
Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis.
Liu J, Lu C, Wu X, Zhang Z, Li J, Guo B
Sci Rep. 2017; 7:41295.
PMID: 28128304
PMC: 5269586.
DOI: 10.1038/srep41295.
Recombinant PTH associated with hypercalcaemia and renal failure.
Ayasreh N, Fernandez-Llama P, Lloret M, Da Silva I, Ballarin J, Bover J
Clin Kidney J. 2016; 6(1):93-95.
PMID: 27818760
PMC: 5094393.
DOI: 10.1093/ckj/sfs148.
Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review).
Nikitovic D, Kavasi R, Berdiaki A, Papachristou D, Tsiaoussis J, Spandidos D
Oncol Rep. 2016; 36(4):1787-92.
PMID: 27499459
PMC: 5022866.
DOI: 10.3892/or.2016.4986.
Management of Hypoparathyroidism: Present and Future.
Bilezikian J, Brandi M, Cusano N, Mannstadt M, Rejnmark L, Rizzoli R
J Clin Endocrinol Metab. 2016; 101(6):2313-24.
PMID: 26938200
PMC: 5393596.
DOI: 10.1210/jc.2015-3910.
Teriparatide for osteoporosis: importance of the full course.
Lindsay R, Krege J, Marin F, Jin L, Stepan J
Osteoporos Int. 2016; 27(8):2395-410.
PMID: 26902094
PMC: 4947115.
DOI: 10.1007/s00198-016-3534-6.
Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S, Fogelman I, Hampson G
J Endocrinol Invest. 2014; 38(1):13-29.
PMID: 25194424
DOI: 10.1007/s40618-014-0152-z.
A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.
Chen J, Yang K, Zhang Z, Chang H, Chen Y, Sowa H
Osteoporos Int. 2014; 26(1):11-28.
PMID: 25138261
DOI: 10.1007/s00198-014-2838-7.
Pharmacological management of osteogenesis.
Nardone V, DAsta F, Brandi M
Clinics (Sao Paulo). 2014; 69(6):438-46.
PMID: 24964310
PMC: 4050321.
DOI: 10.6061/clinics/2014(06)12.
Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidence.
Forslund T, Koski A, Koistinen A, Sikio A
Clin Med Case Rep. 2013; 1:119-22.
PMID: 24179360
PMC: 3785327.
DOI: 10.4137/ccrep.s1026.
Parathyroid hormone reverses radiation induced hypovascularity in a murine model of distraction osteogenesis.
Kang S, Deshpande S, Donneys A, Rodriguez J, Nelson N, Felice P
Bone. 2013; 56(1):9-15.
PMID: 23643680
PMC: 3758112.
DOI: 10.1016/j.bone.2013.04.022.
